Featured image of the article about CircRNA.

LARONDE, ORNA and THERORNA take the lead on circular mRNA therapeutic use

SOPHIA ANTIPOLIS, France – August 09, 2022 | KnowMade noticed recent patenting activity in the field of circular mRNA therapeutics, inspiring us to publish a brief statement about this therapeutic technology. What is a circular mRNA? CircRNA structure & function The first known circular RNA (CircRNA) function is a regulatory function (through miRNA regulation, transcription regulation,[…]

CureVac has acquired Frame Cancer Therapeutics with a promising patent portfolio on neoantigens for mRNA cancer vaccines

SOPHIA ANTIPOLIS, France – June 16, 2022 | CureVac N.V., a German biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA), has announced on June 08th 2022 the acquisition of Frame Cancer Therapeutics (formerly Frame Pharmaceuticals), a startup company based in Netherlands focused on advanced genomics and bioinformatics to identify both unique and shared[…]

Turnkey mRNA therapeutics: what is behind Nutcracker Therapeutics’ technology

SOPHIA ANTIPOLIS, France – April 20, 2022 | During recent decades, biopharmaceuticals have gained considerable attention as revolutionary therapeutics and vaccine strategies, attempting to fulfil the high expectations of resolving serious health conditions. Regarding nucleic acids, mRNA-based technologies have been established as promising approaches in therapy and prevention of numerous diseases. mRNA’s great potential can[…]

Cell-free DNA (dd-cfDNA) transplant assessment test: What is the IP situation behind Natera’s Prospera™ test?

SOPHIA ANTIPOLIS, France – July 07, 2021 | Natera was founded by Matthew Rabinowitz, Ph.D., and Jonathan Sheena, M. Eng, in 2004. This American company provides DNA testing across multiple clinical areas including women’s health, organ health, and oncology. This DNA testing, involving a noninvasive blood-based test, is carried out using its next-generation cfDNA technology[…]